Member access

4-Traders Homepage  >  Shares  >  Nyse  >  Bristol-Myers Squibb Co    BMY   US1101221083

Delayed Quote. Delayed Nyse - 05/29 04:01:21 pm
64.6 USD   -6.58%
05/29DJNew Cancer Immunotherapy Drugs Show Promise -- Update
05/29 Wall St. ends down after weak economic data but gains in May
05/29DJNew Cancer Immunotherapy Drugs Show Promise
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 

Bristol Myers Squibb : Assigned Patent

07/25/2014 | 07:18am US/Eastern

By Targeted News Service

ALEXANDRIA, Va., July 25 -- Bristol-Myers Squibb, Princeton, New Jersey, has been assigned a patent (8,785,398) developed by four co-inventors for the "methods of treatment using CTLA4 mutant molecules." The co-inventors are Robert James Peach, San Diego, Joseph Naemura, Bellevue, Washington, Peter S. Linsley, Seattle, and Jurgen Bajorath, Bonn, Germany.

The patent application was filed on Oct. 20, 2011 (13/277,425). The full-text of the patent can be found at http://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO1&Sect2=HITOFF&d=PALL&p=1&u=%2Fnetahtml%2FPTO%2Fsrchnum.htm&r=1&f=G&l=50&s1=87,85,398.PN.&OS=PN/87,85,398&RS=PN/87,85,398

Written by Sudarshan Harpal; edited by Jaya Anand.

SH0725JA0725-1039881

(c) 2014 Targeted News Service

React to this article
Latest news on BRISTOL-MYERS SQUIBB CO
02:47a BRISTOL MYERS SQUIBB : Secures Positive CHMP Opinion in the European Union for N..
05/29DJNew Cancer Immunotherapy Drugs Show Promise -- Update
05/29 Wall St. ends down after weak economic data but gains in May
05/29DJNew Cancer Immunotherapy Drugs Show Promise
05/29 BRISTOL MYERS SQUIBB : Phase I/II Opdivo (nivolumab) Trial Shows Bristol-Myers S..
05/29 BRISTOL MYERS SQUIBB : Opdivo (nivolumab) First PD-1 Inhibitor to Demonstrate Su..
05/28 BRISTOL MYERS SQUIBB : to Hold Investor Teleconference to Discuss ASCO Highlight..
05/28 BRISTOL MYERS SQUIBB : Gets Positive CHMP Opinion in the European Union for Nivo..
05/28 BRISTOL MYERS SQUIBB : Secures Amended U.S. FDA Breakthrough Therapy Designation..
05/27 BRISTOL MYERS SQUIBB : Researchers from Bristol-Myers Squibb Detail New Studies ..
Advertisement
Chart
Duration : Period :
Bristol-Myers Squibb Co Technical Analysis Chart | BMY | US1101221083 | 4-Traders
Income Statement Evolution
More Financials